A practical reference on Stenabolic: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-23. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
== Health effects == Supplementation with vitamin D is a reliable method for preventing or treating rickets. On the other hand, the effects of vitamin D supplementation on non-skeletal health are uncertain. A review did not find any effect from supplementation on the rates of non-skeletal disease, other than a tentative decrease in mortality in the elderly. Vitamin D supplements do not alter the outcomes for myocardial infarction, stroke or cerebrovascular disease, cancer, bone fractures or knee osteoarthritis. A US Institute of Medicine (IOM) report states: "Outcomes related to cancer, cardiovascular disease and hypertension, and diabetes and metabolic syndrome, falls and physical performance, immune functioning and autoimmune disorders, infections, neuropsychological functioning, and preeclampsia could not be linked reliably with intake of either calcium or vitamin D, and were often conflicting." Evidence for and against each disease state is provided in detail. Some researchers claim the IOM was too definitive in its recommendations and made a mathematical mistake when calculating the blood level of vitamin D associated with bone health. Members of the IOM panel maintain that they used a "standard procedure for dietary recommendations" and that the report is solidly based on the data.
If we cannot destroy the drug menace in America, then it will surely in time destroy us." His strategy involved both treatment and interdiction: "I am proposing the appropriation of additional funds to meet the cost of rehabilitating drug users, and I will ask for additional funds to increase our enforcement efforts to further tighten the noose around the necks of drug peddlers, and thereby loosen the noose around the necks of drug users." He singled out heroin and broadened the scope beyond the US: "To wage an effective war against heroin addiction, we must have international cooperation. In order to secure such cooperation, I am initiating a worldwide escalation in our existing programs for the control of narcotics traffic." Later the same day, Nixon held a news conference at the White House, where he described drug abuse as "America's public enemy number one." He announced, "In order to fight and defeat this enemy, it is necessary to wage a new, all-out offensive. ... This will be a worldwide offensive dealing with the problems of sources of supply ... It will be government wide, pulling together the nine different fragmented areas within the government in which this problem is now being handled, and it will be nationwide in terms of a new educational program." Nixon also stated that the problem wouldn't end with the addiction of soldiers in the Vietnam War. He pledged to ask Congress for a minimum of $350 million for the anti-drug effort (when he took office in 1969, the federal drug budget was $81 million).
=== Poisoning of Emilian Gebrev === In the aftermath of the Skripal poisoning, investigative journalists were able to track some of the people involved also in Bulgaria. This is how another suspected poisoning case dating back to April 2015 during their stay in the country was linked to the Novichok nerve agent. The victim was the Bulgarian arms dealer Emilian Gebrev, who shared two hypotheses why he might have been attacked: The first one links to the fact that his arms manufacturing company Dunarit exports defense equipment to Ukraine. The other one relates to an attempt by an offshore company to take over Dunarit. The takeover attempt was ultimately linked to the influential Bulgarian politician and oligarch Delyan Peevski who has historically been funded by Russia's state-owned VTB Bank. In November 2023 Bulgaria sought the extradition of three Russian GRU officers, Sergey Fedotov, Georgi Gorshkov and Sergey Pavlov, suspected of the poisoning incident. Sergei Fedotov was also the alias used by one of the assassins in the Salisbury poisonings.
निरन्तरान्धकारितदिगन्तरकन्दलदमन्दसुधारसबिन्दुसान्द्रतरघनाघनवृन्द-सन्देहकरस्यन्दमानमकरन्दबिन्दुबन्धुरतरमाकन्दतरुकुलतल्पकल्पमृ-दुळसिकताजालजटिलमूलतलमरुवकमिलदलघुलघुलयकलितरमणीय-पानीयशालिकाबालिकाकरारविन्दगलन्तिकागलदेलालवङ्गपाटलघनसा-रकस्तूरिकातिसौरभमेदुरलघुतरमधुरशीतलतरसलिलधारानिराकरिष्णुत-दीयविमलविलोचनमयूखरेखापसारितपिपासायासपथिकलोकान् In IAST transliteration:
Sources: en.wikipedia.org
== Further reading == Green Analytical Methods and Miniaturized Sample Preparation techniques for Forensic Drug Analysis. 2025. doi:10.1016/C2022-0-02711-2. ISBN 978-0-443-13907-9. Janusz Pawliszyn: Handbook of Solid Phase Microextraction, Chemical Industry Press, 2009. Pawliszyn J.: Solid Phase Microextraction: Theory and Practice, Wiley-VCH, 1997. Pawliszyn J.: Applications of Solid Phase Microextraction, Royal Society of Chemistry, 1999.
Allan Maxam and Walter Gilbert published a DNA sequencing method in 1977 based on chemical modification of DNA and subsequent cleavage at specific bases. Also known as chemical sequencing, this method allowed purified samples of double-stranded DNA to be used without further cloning. This method's use of radioactive labeling and its technical complexity discouraged extensive use after refinements in the Sanger methods had been made. Maxam-Gilbert sequencing requires radioactive labeling at one 5' end of the DNA and purification of the DNA fragment to be sequenced. Chemical treatment then generates breaks at a small proportion of one or two of the four nucleotide bases in each of four reactions (G, A+G, C, C+T). The concentration of the modifying chemicals is controlled to introduce on average one modification per DNA molecule. Thus a series of labeled fragments is generated, from the radiolabeled end to the first "cut" site in each molecule. The fragments in the four reactions are electrophoresed side by side in denaturing acrylamide gels for size separation. To visualize the fragments, the gel is exposed to X-ray film for autoradiography, yielding a series of dark bands each corresponding to a radiolabeled DNA fragment, from which the sequence may be inferred. This method is mostly obsolete as of 2023.
Fatty acid metabolism consists of various metabolic processes involving or closely related to fatty acids, a family of molecules classified within the lipid macronutrient category. These processes can mainly be divided into (1) catabolic processes that generate energy and (2) anabolic processes where they serve as building blocks for other compounds. In catabolism, fatty acids are metabolized to produce energy, mainly in the form of adenosine triphosphate (ATP). When compared to other macronutrient classes (carbohydrates and protein), fatty acids yield the most ATP on an energy per gram basis, when they are completely oxidized to CO2 and water by beta oxidation and the citric acid cycle. Fatty acids (mainly in the form of triglycerides) are therefore the foremost storage form of fuel in most animals, and to a lesser extent in plants. In anabolism, intact fatty acids are important precursors to triglycerides, phospholipids, second messengers, hormones and ketone bodies. For example, phospholipids form the phospholipid bilayers out of which all the membranes of the cell are constructed from fatty acids. Phospholipids comprise the plasma membrane and other membranes that enclose all the organelles within the cells, such as the nucleus, the mitochondria, endoplasmic reticulum, and the Golgi apparatus. In another type of anabolism, fatty acids are modified to form other compounds such as second messengers and local hormones. The prostaglandins made from arachidonic acid stored in the cell membrane are probably the best-known of these local hormones.
=== Structure and bonding === The formaldehyde molecule is Y-shaped and its molecular symmetry belongs to the C2v point group. The precise molecular geometry of gaseous formaldehyde has been determined by gas electron diffraction and microwave spectroscopy. The bond lengths are 1.21 Å for the carbon–oxygen bond and around 1.11 Å for the carbon–hydrogen bond, while the H–C–H bond angle is 117°, close to the 120° angle found in an ideal trigonal planar molecule. Some excited electronic states of formaldehyde are pyramidal rather than planar as in the ground state.
== Reception == 12 Feet Deep received generally positive reviews from critics. JoBlo.com called it a "well crafted-entertaining thriller" and gave it 8/10 stars. That Moment In gave it 3.5/5 stars and said it was "well-directed and engrossing... less a shocker than an intense human drama".
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.